BioWorld

April 26, 2007

Positive 'Restless Legs' Data Send XenoPort Shares Soaring

Shares of XenoPort Inc. leaped 44 percent on news that its gabapentin prodrug, XP13512, met its endpoints in the first of three Phase III studies in restless legs syndrome (RLS). (BioWorld Today) Read More

First Phase III Data Positive With BDSI's Buccal Fentanyl

Cytos, Novartis Enter Potential $500M Deal On Nicotine Vaccine

Genzyme Grows Markets, Beats 1st Quarter Estimates

Poniard's Public Offering Brings In $65M, Mainly For Picoplatin

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026